TOP2A and EZH2 might be biomarkers of disease with increased metastatic potential, according to a genome-wide analysis of data from nine cohorts of patients with primary or metastatic castration-resistant prostate cancer, and one prospective cohort. In addition, in prostate cancer mouse cell line models, concurrent increase of TOP2A and EZH2 led to hypersensitivity to treatment with a combination of the topisomerase II inhibitor etoposide and inhibitors of EZH2.
References
Labbé, D. P. et al. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-17-0413 (2017)
Rights and permissions
About this article
Cite this article
Thoma, C. Potential biomarkers of aggressive disease. Nat Rev Urol 14, 639 (2017). https://doi.org/10.1038/nrurol.2017.169
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.169